Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer. September 8, 2020 READ MORE ⟶ Press Releases Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia July 14, 2020 READ MORE ⟶ Press Releases Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States May 19, 2020 READ MORE ⟶ Press Releases Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners. May 12, 2020 READ MORE ⟶ Press Releases Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program April 28, 2020 READ MORE ⟶ Press Releases The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay December 5, 2019 READ MORE ⟶ Press Releases Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA June 19, 2019 READ MORE ⟶ Press Releases Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies May 21, 2019 READ MORE ⟶ Press Releases Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco January 3, 2019 READ MORE ⟶ Press Releases US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US

Invivoscribe also Receives National Reimbursement for CDx Assay in Japan
November 29, 2018 READ MORE ⟶ Press Releases
Press Releases2019-07-05T02:15:39+00:00
ALL PRESS RELEASES